ESMO Virtual Congress 2020

September 19-21, 2020

Representative: Andriy Krendyukov, M.D., VP Medical Affairs

 

Cambridge Healthtech Institute's 8th Annual Immuno-Oncology Virtual Summit

October 6-8, 2020

Representative: Katharina Billian-Frey, Ph.D., Head of Protein Engineering

Presentation: October 7, 1:15 pm EDT: "HERA-CD40L: A Two-Fold-Three-Based CD40 Agonist for Cancer Immunotherapy"
(Session: Emerging Targets and Combinations to Overcome Resistance to Immune Therapy)

 

Presentations and Posters from Past Conferences

AACR Virtual Annual Meeting II

June 22-24, 2020

Poster #4460:Novel bispecific molecules combining HERA-CD40L with anti-CEA or with anti-PD-L1 for targeting

Poster #4529: Neutralization of pro-apoptotic CD95L by Asunercept/APG101 does not impair anti-tumor immune responses

Presentation #1076: Hexavalent HERA-CD40L induces a productive T cell-mediated anti-tumor immune response and shows superior activity in comparison to benchmark CD40 agonistic antibodies